Combining neuromodulation and mindfulness for alcohol dependence

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to integrate transcutaneous vagus nerve stimulation (tVNS) and mindfulness meditation within a structured mindfulness-based relapse prevention (MBRP) program for patients recovering from alcohol dependence. The researchers will evaluate whether neuromodulation enhances the effectiveness of mindfulness practices compared to mindfulness alone. They will measure changes in drinking behavior, cravings, and abstinence rates for up to three months post-treatment, while also investigating the role of brain oscillations in cognitive control during meditation exercises. The study focuses on detoxified alcohol-dependent individuals who have maintained abstinence for varying durations.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Alcohol Dependence (ICD-10)
* abstinence between 3 days and 12 months

Exclusion Criteria:

* current (last 12 months) substance use disorder/dependence
* neurological disorders (e.g. epilepsy, neuropathy, multiple sclerosis)
* current severe major depressive disorder, manic episode or schizophreniform disorder
* intake of anticonvulsive or high-potency antipsychotic medication

Where it's running

• Charité - Berlin University of Medicine
  Berlin, State of Berlin, Germany Recruiting

Study contacts

• Principal investigator: Anne Beck, Prof. Dr. — Faculty of Health Sciences, Health and Medical University, University of Potsdam, Potsdam, Germany
• Study coordinator: Annika Rosenthal
• Email: annika.rosenthal@charite.de
• Phone: 030 450 517040

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• BrainsWay Deep Transcranial Magnetic Stimulation (Deep TMS) for adults with alcohol use disorder

  This study will test whether BrainsWay Deep TMS can reduce heavy drinking in adults with moderate to severe alcohol use disorder compared with a sham procedure.

  Recruiting at 9 sites Brainsway · Tuscaloosa, Alabama and 10 other locations · NCT07216872

• Tirzepatide's effects on alcohol intake in patients with schizophrenia and alcohol use disorder

  This study is testing if the medication tirzepatide can help people with schizophrenia and alcohol use disorder drink less alcohol over six months.

  Recruiting at 2 sites Phase 2 Psychiatric Centre Rigshospitalet · Aalborg, Denmark and 1 other locations · NCT06939088

• Exploring the effects of heavy alcohol use on oral health and saliva

  This study is trying to see how heavy drinking affects oral health and inflammation in people with alcohol use disorder compared to those without it.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT06684483

• Validation of the French version of the PAWSS scale for alcohol withdrawal prediction

  This study is testing a French version of a scale to see if it can accurately predict alcohol withdrawal symptoms in people with alcohol use disorders who are in the hospital.

  Recruiting Etablissement Public de Santé Barthélemy Durand · Étampes · NCT06675539

• Psilocybin versus ketamine for reducing heavy drinking in alcohol use disorder

  This trial will test whether a single 30 mg dose of psilocybin or a weight-based 0.75 mg/kg dose of ketamine, each given with individual psychotherapy, can reduce heavy drinking in adults with moderate to severe alcohol use disorder.

  Recruiting Phase 2 University of Iowa · Iowa City, Iowa · NCT06405607

• Telehealth program using blood tests to help treat alcohol use disorder

  This study is testing a new telehealth program that uses blood tests to help people with alcohol use disorder by combining online therapy with rewards for submitting their test results.

  Recruiting Washington State University · Spokane, Washington · NCT06265506

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.